PMID- 22586420
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 1664-302X (Electronic)
IS  - 1664-302X (Linking)
VI  - 3
DP  - 2012
TI  - The role of adjuvants in therapeutic protection against paracoccidioidomycosis 
      after immunization with the P10 peptide.
PG  - 154
LID - 10.3389/fmicb.2012.00154 [doi]
LID - 154
AB  - Paracoccidioidomycosis (PCM), a common chronic mycosis in Latin America, is a 
      granulomatous systemic disease caused by the thermo-dimorphic fungus 
      Paracoccidioides brasiliensis. The glycoprotein gp43 is the main antigen target 
      of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known as P10, 
      defines a major CD4(+)-specific T cell epitope. Previous results have indicated 
      that, besides having a preventive role in conventional immunizations prior to 
      challenge with the fungus, protective anti-fungal effects can be induced in P. 
      brasiliensis-infected mice treated with P10 administered with complete Freund's 
      adjuvant (CFA). The peptide elicits an IFN-gamma-dependent Th1 immune response and is 
      the main candidate for effective immunotherapy of patients with PCM, as an 
      adjunctive approach to conventional chemotherapy. In the present study we tested 
      the therapeutic effects of P10 combined with different adjuvants [aluminum 
      hydroxide, CFA, flagellin, and the cationic lipid dioctadecyl-dimethylammonium 
      bromide (DODAB)] in BALB/c mice previously infected with the P. brasiliensis Pb18 
      strain. Significant reductions in the number of colony forming units of the 
      fungus were detected in lungs of mice immunized with P10 associated with the 
      different adjuvants 52 days after infection. Mice treated with DODAB and P10, 
      followed by mice treated with P10 and flagellin, showed the most prominent 
      effects as demonstrated by the lowest numbers of viable yeast cells as well as 
      reductions in granuloma formation and fibrosis. Concomitantly, secretion of IFN-gamma 
      and TNF-alpha, in contrast to interleukin (IL)-4 and IL-10, was enhanced in the lungs 
      of mice immunized with P10 in combination with the tested adjuvants, with the 
      best results observed in mice treated with P10 and DODAB. In conclusion, the 
      present results demonstrate that the co-administration of the synthetic P10 
      peptide with several adjuvants, particularly DODAB, have significant therapeutic 
      effects in experimental PCM.
FAU - Mayorga, Oriana
AU  - Mayorga O
AD  - Department of Microbiology, Biomedical Sciences Institute of University of Sao 
      Paulo, Sao Paulo, Sao Paulo, Brazil.
FAU - Munoz, Julian E
AU  - Munoz JE
FAU - Lincopan, Nilton
AU  - Lincopan N
FAU - Teixeira, Aline F
AU  - Teixeira AF
FAU - Ferreira, Luis C S
AU  - Ferreira LC
FAU - Travassos, Luiz R
AU  - Travassos LR
FAU - Taborda, Carlos P
AU  - Taborda CP
LA  - eng
PT  - Journal Article
DEP - 20120504
PL  - Switzerland
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC3343455
OTO - NOTNLM
OT  - FliC flagellin
OT  - P10
OT  - Paracoccidioides brasiliensis
OT  - adjuvants
OT  - aluminum hydroxide
OT  - complete Freund's adjuvant
OT  - dioctadecyl-dimethylammonium bromide
OT  - paracoccidioidomycosis
EDAT- 2012/05/16 06:00
MHDA- 2012/05/16 06:01
PMCR- 2012/05/04
CRDT- 2012/05/16 06:00
PHST- 2012/03/02 00:00 [received]
PHST- 2012/04/03 00:00 [accepted]
PHST- 2012/05/16 06:00 [entrez]
PHST- 2012/05/16 06:00 [pubmed]
PHST- 2012/05/16 06:01 [medline]
PHST- 2012/05/04 00:00 [pmc-release]
AID - 10.3389/fmicb.2012.00154 [doi]
PST - epublish
SO  - Front Microbiol. 2012 May 4;3:154. doi: 10.3389/fmicb.2012.00154. eCollection 
      2012.